XELOX Vs. FOLFOX in Metastatic Colorectal Cancer: An Updated Meta-analysis

Overview

Journal Cancer Invest

Specialty Oncology

Date 2016 Feb 12

PMID 26864862

Citations 37

Authors

Yu Guo

Bing-Hong Xiong

Tao Zhang

Yong Cheng

Li Ma

Affiliations

Soon will be listed here.

Abstract

This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety. Only randomized controlled trials (RCTs) comparing XELOX versus FOLFOX were included. A total of 4,363 patients from eight RCTs were available for analysis. Pooled analysis revealed that there were no statistical differences between both arms in OS, and ORR. XELOX arm had a higher incidence of thrombocytopenia, hand-foot syndrome, and diarrhea, whereas neutropenia had a higher incidence in the FOLFOX group. For mCRC, the effect of XELOX is similar to FOLFOX.

Citing Articles

Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial.

Karbasforooshan H, Rahimi H, Arasteh O, Allahyari A, Varmaghani M, Jannati M Iran J Pharm Res. 2025; 23(1):e152364.

PMID: 40066113 PMC: 11892790. DOI: 10.5812/ijpr-152364.

Localized Drug Delivery in Different Gastrointestinal Cancers: Navigating Challenges and Advancing Nanotechnological Solutions.

Hasan A, Cavalu S, Kira A, Hamad R, Abdel-Reheim M, Elmorsy E Int J Nanomedicine. 2025; 20():741-770.

PMID: 39845772 PMC: 11752831. DOI: 10.2147/IJN.S502833.

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US.

Paly V, Dasari A, Hubbard J, Bekaii-Saab T, Padukkavidana T, Hernandez L J Comp Eff Res. 2024; 13(8):e240084.

PMID: 38976346 PMC: 11284812. DOI: 10.57264/cer-2024-0084.

β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo.

Deng M, Yan P, Gong H, Li G, Wang J Mol Med. 2024; 30(1):95.

PMID: 38910244 PMC: 11194918. DOI: 10.1186/s10020-024-00864-1.

The Exposome and Nutritional Pharmacology and Toxicology: A New Application for Metabolomics.

Rushing B, Thessen A, Soliman G, Ramesh A, Sumner S Exposome. 2024; 3(1.

PMID: 38766521 PMC: 11101153. DOI: 10.1093/exposome/osad008.